shutout 2,6 g/seringă
intervet international bv, Țările de jos - subnitrat de bismut - suspensie pentru administrare intramamară - alte medicamente - bovine - bovine (vaci de lapte la înțărcare) prevenirea infecțiilor intramamare noi în timpul perioadei de repaus mamar. la vacile considerate a fi indemne de mastită subclinică, shutout poate fi utilizat singur în managementul vacilor aflate în perioada de repaus mamar și controlul mastitelor.
octreotide acetate 0,1mg/ml soluţie injectabilă
beijing shuanglu pharmaceutical co., ltd - octreotidum - soluţie injectabilă - 0,1mg/ml
soliris
alexion europe sas - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - soliris este indicat la adulți și copii pentru tratamentul:hemoglobinurie paroxistică nocturnă (hpn). dovezi de beneficii clinice este demonstrată la pacienții cu hemoliză cu simptom clinic(s) indică un grad înalt de activitate a bolii, indiferent de transfuzie istorie (a se vedea secțiunea 5. atipic sindrom hemolitic-uremic (ahus). soliris este indicat la adulți pentru tratamentul:refractare generalizate miastenia gravis (gmg) la pacienții care sunt anti-receptorilor de acetilcolină (achr) anticorpi-pozitiv (a se vedea secțiunea 5. oftalmoneuromielită optica tulburare de spectru (nmosd) la pacienții care sunt anti-aquaporin-4 (aqp4) anticorpi pozitiv cu un curs recurente ale bolii.
ultomiris
alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
proteza modulara, de coapsa, cu shuttle lock
sc theranova protezare srl -
epysqli
samsung bioepis nl b.v. - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
ceftazidime for injection 0,5 g pulbere pentru soluţie injectabilă/perfuzabilă
guangxi kelun pharmaceutical co., ltd - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 0,5 g
heparin-indar 5000 ui/ml soluţie injectabilă
indar sap pentru producerea insulinelor - heparini de sodiu - soluţie injectabilă - 5000 ui/ml
gemcitabine liofilizat pentru solutie injectabila 1 g
neon laboratories limited - gemcitabinum - liofilizat pentru solutie injectabila - 1 g
gemcitabine liofilizat pentru solutie injectabila 200 mg
neon laboratories limited - gemcitabinum - liofilizat pentru solutie injectabila - 200 mg